Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% ...
A deep dive into how pharma funding shapes medical narratives, how the status quo perpetuates itself, and why science isn’t the meritocracy we imagine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results